Raiffeisen Bank International’s Iovance Biotherapeutics IOVA Stock Holding History

Raiffeisen Bank International’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Hold	380,000	–	–	0.02%	347
2026 Q1	$1.26M	Sell	380,000 -70,000	-16%	-$224K	0.02%	362
2025 Q4	$1.25M	Buy	450,000 +210,000	+88%	+$486K	0.02%	316
2025 Q3	$535K	Buy	240,000 +93,000	+63%	+$220K	0.01%	411
2025 Q2	$262K	Hold	147,000	–	–	﹤0.01%	410
2025 Q1	$523K	Buy	147,000 +45,000	+44%	+$232K	0.01%	365
2024 Q4	$732K	Buy	+102,000	New	+$945K	0.01%	307

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Raiffeisen Bank International's IOVA Position: Q2 2026 in Review

Raiffeisen Bank International held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 380,000 shares worth $1.6M. The position accounts for 0.02% of the portfolio, ranked #347.

Raiffeisen Bank International first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Raiffeisen Bank International held 380,000 shares of Iovance Biotherapeutics worth $1.6M as of Q2 2026.
Raiffeisen Bank International left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up 0.02% of Raiffeisen Bank International's portfolio in Q2 2026, its #347 holding.
Raiffeisen Bank International first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.